PMID- 28736442
OWN - NLM
STAT- MEDLINE
DCOM- 20180920
LR  - 20181113
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Print)
IS  - 0307-0565 (Linking)
VI  - 41
IP  - 11
DP  - 2017 Nov
TI  - Family history of type 2 diabetes, abdominal adipocyte size and markers of the 
      metabolic syndrome.
PG  - 1621-1626
LID - 10.1038/ijo.2017.171 [doi]
AB  - BACKGROUND/OBJECTIVES: A major risk factor of type 2 diabetes mellitus (T2DM) is 
      a positive family history of diabetes. First degree relatives (FDR) of patients 
      with T2DM are more insulin resistant and are reported to have larger abdominal 
      subcutaneous adipocytes than adults without a family history. Our objectives were 
      to assess whether FDR of T2DM are associated with larger abdominal adipocytes 
      independent of age, sex and abdominal subcutaneous fat and to assess whether a 
      family history of T2DM is also independently related to femoral adipocyte size, 
      as well as visceral fat and fasting plasma triglyceride (TG) concentrations. 
      METHODS: We extracted adipocyte size, body composition, plasma TG and demographic 
      data of non-diabetic research participants of previous studies conducted in our 
      laboratory. We ascertained the family history of T2DM from the electronic medical 
      records. Multivariate regression analysis was used to assess whether FDR of T2DM 
      are more likely to have other risk factors after adjusting for known covariates. 
      RESULTS: Of 604 participants, 148 were FDR of T2DM. Although abdominal and 
      femoral adipocyte size was greater in FDR of T2DM than those without a family 
      history (0.74+/-0.33 vs 0.63+/-0.33 mug lipid per cell, P<0.001; 0.81+/-0.29 vs 
      0.72+/-0.33 mug lipid per cell, P=0.01, respectively), this was confounded by FDR of 
      T2DM being older, having greater body mass index and percent body fat. A family 
      history of T2DM was a significant predictor of abdominal adipocyte size after 
      adjustment for age and body fat distribution parameters in females (total 
      R(2)=0.5, P<0.0001), but not in males. A family history of T2DM was not 
      independently predictive of femoral adipocyte size, visceral fat area or TG. 
      CONCLUSIONS: Female FDR of T2DM have larger abdominal, but not femoral, 
      adipocytes, even after accounting for age and body fat distribution.
FAU - Anthanont, P
AU  - Anthanont P
AD  - Endocrine Research Unit, Mayo Clinic, 200 First Street Southwest, Room 5-194, 
      Rochester, MN 55905, USA.
FAU - Ramos, P
AU  - Ramos P
AD  - Endocrine Research Unit, Mayo Clinic, 200 First Street Southwest, Room 5-194, 
      Rochester, MN 55905, USA.
FAU - Jensen, M D
AU  - Jensen MD
AD  - Endocrine Research Unit, Mayo Clinic, 200 First Street Southwest, Room 5-194, 
      Rochester, MN 55905, USA.
FAU - Hames, K C
AU  - Hames KC
AD  - Endocrine Research Unit, Mayo Clinic, 200 First Street Southwest, Room 5-194, 
      Rochester, MN 55905, USA.
LA  - eng
GR  - K12 HD065987/HD/NICHD NIH HHS/United States
GR  - P30 DK050456/DK/NIDDK NIH HHS/United States
GR  - R37 DK040484/DK/NIDDK NIH HHS/United States
GR  - R01 DK040484/DK/NIDDK NIH HHS/United States
GR  - UL1 TR000135/TR/NCATS NIH HHS/United States
GR  - R01 DK045343/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170724
PL  - England
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
RN  - 0 (Biomarkers)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Adipocytes/*pathology
MH  - Adult
MH  - Biomarkers/metabolism
MH  - Body Fat Distribution
MH  - Body Mass Index
MH  - Cell Size
MH  - Diabetes Mellitus, Type 2/genetics/*metabolism/physiopathology
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Insulin Resistance/*genetics
MH  - Male
MH  - Metabolic Syndrome/genetics/*metabolism/physiopathology
MH  - Risk Factors
MH  - Sex Factors
MH  - Triglycerides/metabolism
PMC - PMC5818259
MID - NIHMS892577
COIS- Conflict of interest The authors have no conflict of interest to disclose.
EDAT- 2017/07/25 06:00
MHDA- 2018/09/21 06:00
PMCR- 2018/02/19
CRDT- 2017/07/25 06:00
PHST- 2017/01/26 00:00 [received]
PHST- 2017/06/27 00:00 [revised]
PHST- 2017/07/11 00:00 [accepted]
PHST- 2017/07/25 06:00 [pubmed]
PHST- 2018/09/21 06:00 [medline]
PHST- 2017/07/25 06:00 [entrez]
PHST- 2018/02/19 00:00 [pmc-release]
AID - ijo2017171 [pii]
AID - 10.1038/ijo.2017.171 [doi]
PST - ppublish
SO  - Int J Obes (Lond). 2017 Nov;41(11):1621-1626. doi: 10.1038/ijo.2017.171. Epub 
      2017 Jul 24.